Molecular simulation driven experiment for formulation of fixed dose combination of Darunavir and Ritonavir as anti-HIV nanosuspension

Chetan Hasmukh Mehta, Reema Narayan, Gururaj Aithal, Sudharsan Pandiyan, Pritesh Bhat, Swapnil Dengale, Abhishek Shah, Usha Yogendra Nayak, Sanjay Garg

Research output: Contribution to journalArticle

Abstract

In this study, we designed a fixed-dose combination (FDC) for Darunavir (DRV) and Ritonavir (RTV) using molecular simulations as a tool. Molecular modeling allowed us to choose the solvent and antisolvent required for the formation of nanosuspension by estimating the solubility parameter. Molecular dynamics simulations and the analysis of the same provided useful information at the molecular level. Hydrogen bonding interactions, radial distribution functions, the radius of gyration, diffusion coefficient, and density profile analysis allowed us to see the formation of particles virtually. With the information obtained from the simulations, we were able to design our experiments and found that the results from experiments complemented the findings from the simulations. Nanosuspension was prepared by using high-speed homogenization (HSH) followed by probe sonication. The solid-state characterization studies demonstrated that both the drugs remain in the amorphous form with absence of any intermolecular interactions. The pharmacokinetic study indicated a significant improvement in the oral bioavailability of DRV/RTV nanosuspension compared to the pure drug combination. Thus, the studies demonstrated that the developed FDC nanosuspension could be a useful alternative dosage form for treating human immunodeficiency virus (HIV) infected patients.

Original languageEnglish
Article number111469
JournalJournal of Molecular Liquids
Volume293
DOIs
Publication statusPublished - 01-11-2019

Fingerprint

Ritonavir
human immunodeficiency virus
Viruses
formulations
dosage
Molecular modeling
Pharmacokinetics
Sonication
Dosage Forms
Drug Combinations
Distribution functions
Molecular dynamics
Hydrogen bonds
drugs
simulation
Solubility
Experiments
bioavailability
experiment design
gyration

All Science Journal Classification (ASJC) codes

  • Electronic, Optical and Magnetic Materials
  • Atomic and Molecular Physics, and Optics
  • Condensed Matter Physics
  • Spectroscopy
  • Physical and Theoretical Chemistry
  • Materials Chemistry

Cite this

Mehta, Chetan Hasmukh ; Narayan, Reema ; Aithal, Gururaj ; Pandiyan, Sudharsan ; Bhat, Pritesh ; Dengale, Swapnil ; Shah, Abhishek ; Nayak, Usha Yogendra ; Garg, Sanjay. / Molecular simulation driven experiment for formulation of fixed dose combination of Darunavir and Ritonavir as anti-HIV nanosuspension. In: Journal of Molecular Liquids. 2019 ; Vol. 293.
@article{91425d05f0b64426958d00e5182f51d1,
title = "Molecular simulation driven experiment for formulation of fixed dose combination of Darunavir and Ritonavir as anti-HIV nanosuspension",
abstract = "In this study, we designed a fixed-dose combination (FDC) for Darunavir (DRV) and Ritonavir (RTV) using molecular simulations as a tool. Molecular modeling allowed us to choose the solvent and antisolvent required for the formation of nanosuspension by estimating the solubility parameter. Molecular dynamics simulations and the analysis of the same provided useful information at the molecular level. Hydrogen bonding interactions, radial distribution functions, the radius of gyration, diffusion coefficient, and density profile analysis allowed us to see the formation of particles virtually. With the information obtained from the simulations, we were able to design our experiments and found that the results from experiments complemented the findings from the simulations. Nanosuspension was prepared by using high-speed homogenization (HSH) followed by probe sonication. The solid-state characterization studies demonstrated that both the drugs remain in the amorphous form with absence of any intermolecular interactions. The pharmacokinetic study indicated a significant improvement in the oral bioavailability of DRV/RTV nanosuspension compared to the pure drug combination. Thus, the studies demonstrated that the developed FDC nanosuspension could be a useful alternative dosage form for treating human immunodeficiency virus (HIV) infected patients.",
author = "Mehta, {Chetan Hasmukh} and Reema Narayan and Gururaj Aithal and Sudharsan Pandiyan and Pritesh Bhat and Swapnil Dengale and Abhishek Shah and Nayak, {Usha Yogendra} and Sanjay Garg",
year = "2019",
month = "11",
day = "1",
doi = "10.1016/j.molliq.2019.111469",
language = "English",
volume = "293",
journal = "Journal of Molecular Liquids",
issn = "0167-7322",
publisher = "Elsevier",

}

Molecular simulation driven experiment for formulation of fixed dose combination of Darunavir and Ritonavir as anti-HIV nanosuspension. / Mehta, Chetan Hasmukh; Narayan, Reema; Aithal, Gururaj; Pandiyan, Sudharsan; Bhat, Pritesh; Dengale, Swapnil; Shah, Abhishek; Nayak, Usha Yogendra; Garg, Sanjay.

In: Journal of Molecular Liquids, Vol. 293, 111469, 01.11.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Molecular simulation driven experiment for formulation of fixed dose combination of Darunavir and Ritonavir as anti-HIV nanosuspension

AU - Mehta, Chetan Hasmukh

AU - Narayan, Reema

AU - Aithal, Gururaj

AU - Pandiyan, Sudharsan

AU - Bhat, Pritesh

AU - Dengale, Swapnil

AU - Shah, Abhishek

AU - Nayak, Usha Yogendra

AU - Garg, Sanjay

PY - 2019/11/1

Y1 - 2019/11/1

N2 - In this study, we designed a fixed-dose combination (FDC) for Darunavir (DRV) and Ritonavir (RTV) using molecular simulations as a tool. Molecular modeling allowed us to choose the solvent and antisolvent required for the formation of nanosuspension by estimating the solubility parameter. Molecular dynamics simulations and the analysis of the same provided useful information at the molecular level. Hydrogen bonding interactions, radial distribution functions, the radius of gyration, diffusion coefficient, and density profile analysis allowed us to see the formation of particles virtually. With the information obtained from the simulations, we were able to design our experiments and found that the results from experiments complemented the findings from the simulations. Nanosuspension was prepared by using high-speed homogenization (HSH) followed by probe sonication. The solid-state characterization studies demonstrated that both the drugs remain in the amorphous form with absence of any intermolecular interactions. The pharmacokinetic study indicated a significant improvement in the oral bioavailability of DRV/RTV nanosuspension compared to the pure drug combination. Thus, the studies demonstrated that the developed FDC nanosuspension could be a useful alternative dosage form for treating human immunodeficiency virus (HIV) infected patients.

AB - In this study, we designed a fixed-dose combination (FDC) for Darunavir (DRV) and Ritonavir (RTV) using molecular simulations as a tool. Molecular modeling allowed us to choose the solvent and antisolvent required for the formation of nanosuspension by estimating the solubility parameter. Molecular dynamics simulations and the analysis of the same provided useful information at the molecular level. Hydrogen bonding interactions, radial distribution functions, the radius of gyration, diffusion coefficient, and density profile analysis allowed us to see the formation of particles virtually. With the information obtained from the simulations, we were able to design our experiments and found that the results from experiments complemented the findings from the simulations. Nanosuspension was prepared by using high-speed homogenization (HSH) followed by probe sonication. The solid-state characterization studies demonstrated that both the drugs remain in the amorphous form with absence of any intermolecular interactions. The pharmacokinetic study indicated a significant improvement in the oral bioavailability of DRV/RTV nanosuspension compared to the pure drug combination. Thus, the studies demonstrated that the developed FDC nanosuspension could be a useful alternative dosage form for treating human immunodeficiency virus (HIV) infected patients.

UR - http://www.scopus.com/inward/record.url?scp=85070860653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070860653&partnerID=8YFLogxK

U2 - 10.1016/j.molliq.2019.111469

DO - 10.1016/j.molliq.2019.111469

M3 - Article

VL - 293

JO - Journal of Molecular Liquids

JF - Journal of Molecular Liquids

SN - 0167-7322

M1 - 111469

ER -